A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion

Abstract The pathogenesis of retinal vein occlusion (RVO), has not been well understood. Recent data have shown the efficacy of an anticoagulant therapy with LMWHs in the treatment of acute RVO suggesting the presence of a hypercoagulable state in these patients. New global tests for detection of hy...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2012-09, Vol.224 (1), p.97-101
Main Authors: Cellai, Anna Paola, Lami, Donatella, Fedi, Sandra, Marcucci, Rossella, Mannini, Lucia, Cenci, Caterina, Rogolino, Angela, Sodi, Andrea, Menchini, Ugo, Abbate, Rosanna, Prisco, Domenico
Format: Article
Language:English
Subjects:
Adult
Aged
anticoagulants
atherosclerosis
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular
Clot lysis time
coagulation
Endogenous thrombin potential
Female
Fibrin Clot Lysis Time
Humans
Male
males
Medical sciences
Middle Aged
multivariate analysis
pathogenesis
pathophysiology
patients
Retinal vein occlusion
Retinal Vein Occlusion - diagnosis
Retinal Vein Occlusion - etiology
Retinal Vein Occlusion - physiopathology
risk factors
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
therapeutics
Thrombin
Thrombophilia - complications
Thrombophilia - diagnosis
Tissue factor pathway inhibitor
Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The pathogenesis of retinal vein occlusion (RVO), has not been well understood. Recent data have shown the efficacy of an anticoagulant therapy with LMWHs in the treatment of acute RVO suggesting the presence of a hypercoagulable state in these patients. New global tests for detection of hypercoagulability and hypofibrinolysis have become available and their application might improve the knowledge of the pathophysiology of RVO and, potentially, its treatment. The aim of our study was to evaluate coagulation and fibrinolytic alterations by two global tests in RVO patients: Endogenous Thrombin Potential (ETP) and Clot Lysis Time (CLT), respectively. We studied 81 RVO patients (40 males; median age 61 years) and a control group matched for age and sex. The ETP was measured by functional chromogenic assay and expressed as the time until thrombin burst (LagTime), Time to peak ( Tmax ), Peak amount of thrombin generation ( Cmax ) and ETP. CLT was determined by a plasma-based, tissue factor-induced clot lysis assay. Cmax , ETP and CLT values were significantly higher in RVO patients than in controls ( Cmax p  = 0.010; ETP p  
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2012.06.053